Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 9/20 | 0.50 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | MERTK | Q12866 | 1/20 | 0.43 |
| ▸ | STK10 | O94804 | 1/20 | 0.40 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717565 | 0.85 | MERTK (0.55) | ABCG2FGFR4VCAM1SYKMAPT | |
| SCHEMBL9984889 | 0.82 | FGFR4 (0.49) | ABCG2FGFR4MAPTPIN1 | |
| SCHEMBL1600402 | 0.80 | PIN1 (0.65) | ABCG2FGFR4MAPTPIN1 | |
| SCHEMBL6796348 | 0.80 | MAPT (0.53) | ABCG2SYKMAPT | |
| SCHEMBL1429473 | 0.78 | ABCG2 (0.50) | ABCG2SYKMAPT | |
| SCHEMBL16854711 | 0.78 | SYK (0.46) | ABCG2SYKMAPTSTK10SLK | |
| SCHEMBL9984184 | 0.77 | MAPT (0.49) | FGFR4MAPT | |
| SCHEMBL29392518 | 0.77 | FGFR4 (0.49) | FGFR4VCAM1MAPTPIN1MERTK | |
| SCHEMBL18766140 | 0.77 | FGFR4 (0.49) | FGFR4VCAM1MAPTPIN1MERTK | |
| SCHEMBL14762497 | 0.75 | FGFR4 (0.51) | ABCG2FGFR4SYKMAPTPIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300469-B1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| US-8507488-B2 | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-8507488-B2 | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-8507488-B2 | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-20110306606-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | DONG WHA PHARM. CO., LTD. (KR) | 2011-12-15 | — | — | US | disclosed |
| EP-2394993-A2 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Dong Wha Pharm. Co., Ltd. (KR) | 2011-12-14 | — | — | EP | disclosed |
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-07-07 | — | — | US | disclosed |
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-07-07 | — | — | US | disclosed |
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-07-07 | — | — | US | disclosed |
| EP-2300469-A2 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009140128-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009140128-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306606-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | NOS3, PTMS, NOS2 | ABCG2 3694/4885FGFR4 1689/4885VCAM1 946/4885 |
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | ALK, ROS1, FLT3 | ABCG2 3396/4885FGFR4 32/4885VCAM1 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.